LGM
Logos Global Management Portfolio holdings
AUM
$1.01B
1-Year Est. Return
90.41%
1 Year Est. Return
+90.41%
AUM
$749M
AUM Growth
+$186M
(+33%)
Holding
60
Top Buys
| 1 | +$47.8M | |
| 2 | +$25.1M | |
| 3 | +$24.4M | |
| 4 |
Arvinas
ARVN
|
+$24.3M |
| 5 |
Neurocrine Biosciences
NBIX
|
+$18.9M |
Top Sells
| 1 | +$35.5M | |
| 2 | +$26.1M | |
| 3 | +$21.8M | |
| 4 |
BioNTech
BNTX
|
+$18.2M |
| 5 |
ETNB
89bio
ETNB
|
+$18.2M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
CMPS
51
Compass Pathways
CMPS
$702M
| – | – |
-2,000,000
|
|
||
52
Crinetics Pharmaceuticals
CRNX
$5.78B
| – | – |
-350,000
|
|
||
|
ETNB
53
DELISTED
89bio
ETNB
| – | – |
-2,500,000
|
|
||
54
Geron
GERN
$830M
| – | – |
-8,000,000
|
|
||
55
Larimar Therapeutics
LRMR
$271M
| – | – |
0
|
|
||
56
Nuvalent
NUVL
$8.24B
| – | – |
-500,000
|
|
||
57
Solid Biosciences
SLDB
$441M
| – | – |
-100,000
|
|
||
58
Soleno Therapeutics
SLNO
$2.25B
| – | – |
-250,000
|
|
||
59
Teva Pharmaceuticals
TEVA
$37.1B
| – | – |
-1,700,000
|
|
||
60
State Street SPDR S&P Biotech ETF
XBI
$8.68B
| – | – |
0
|
|